Verbrinacogene setparvovec

司沃贝考基

Report date: 2023/10/26 16:04:05

Base Information

Drug NameVerbrinacogene setparvovec
Drug Alias NameFLT-180a
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV3 vector
Mechanisms of ActionBlood coagulation pathway activationCoagulation factor IX modulatorsFactor IX gene transference
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyIreland +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSpur Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSpur TherapeuticsUniversity College London
Active IndicationsN/A
Inactive IndicationsHemophilia B

Other Information

ATC CodeN/A
Related LinksN/A